Should Steroids Be Given for Pneumonitis?
Yes, systemic corticosteroids are strongly recommended as first-line treatment for symptomatic pneumonitis, particularly immune checkpoint inhibitor (ICI)-related pneumonitis, with clinical improvement reported in >80% of cases 1.
Treatment Algorithm by Severity Grade
Grade 1 (Asymptomatic)
- Monitor closely without steroids
- Continue surveillance imaging
Grade 2 (Symptomatic but not severe)
- Discontinue the offending agent immediately 2
- Initiate corticosteroids (typically prednisone 0.5-1 mg/kg/day or equivalent) 1, 2
- All major guidelines (ASCO, NCCN, ESMO) recommend corticosteroid treatment at this grade 2
Grade 3-4 (Severe/Life-threatening)
- Permanently discontinue ICIs 2
- High-dose corticosteroids (methylprednisolone 1-2 mg/kg/day IV or equivalent) 1
- Hospitalization required for monitoring and supportive care 2
- Supplemental oxygen or mechanical ventilation as needed 2
Steroid-Refractory Disease
If no clinical improvement occurs after 48 hours of corticosteroid therapy, the pneumonitis is deemed steroid-refractory 1. At this point:
- Consider second-line immunosuppressive agents:
Critical caveat: Steroid-refractory/resistant ICI-pneumonitis carries a 67% mortality rate at 2 months despite second-line therapy 3. This occurs in approximately 10% of ICI-pneumonitis cases treated with steroids 3.
Key Clinical Considerations
Early diagnosis is paramount - delayed recognition leads to higher severity, less reversibility, and residual fibrotic damage 2. The median time to onset is 34 weeks but ranges from 1.5-127 weeks 1.
Workup essentials:
- Pulse oximetry and contrast-enhanced chest CT
- Rule out infection (nasal swab, sputum/blood/urine cultures) for Grade 2 or higher 1
- Transbronchial biopsy generally not required unless ruling out infection, tumor progression, or chronic organizing pneumonia 1
Radiologic patterns include ground-glass opacities, patchy nodular infiltrates (predominantly lower lobes), with five distinct subtypes described 1.
Is There a Scoring System for Steroid Complications?
No validated scoring system exists specifically for predicting steroid-related complications in pneumonitis treatment. However, the evidence shows:
- Hyperglycemia is the primary short-term complication requiring monitoring 5
- No significant increase in healthcare-associated infections, gastrointestinal bleeding, or acute kidney injury with short-term steroid use in severe pneumonia 6, 5
- Hospital-acquired infections show no difference (RR 0.99 for severe pneumonia, RR 0.97 for ARDS) 6
The grading system used is the Common Terminology Criteria for Adverse Events (CTCAE) for pneumonitis severity (Grades 1-4), which guides treatment intensity rather than predicting steroid complications 1, 3.
Important Pitfalls
Preexisting interstitial lung disease (ILD) is a major risk factor for developing drug-related pneumonitis, with odds ratios ranging from 4.8 to 25.3 depending on ILD severity 2. These patients require heightened surveillance.
Chronic pneumonitis can persist despite ICI discontinuation and may not resolve after >3 months of corticosteroids, occurring in approximately 2% of patients 1.
Steroid withdrawal timing matters - premature discontinuation during active pneumonitis leads to accelerated mortality within 2-4 weeks, though withdrawal after pneumonitis resolution does not increase risk 7.